The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TPG Asia VII SF Pte Ltd
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Smallcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TPG Asia VII SF Pte. Ltd, a Singapore-based private equity investor, has sold 2,08,41,439 equity shares (10.00% of total share capital) of Sai Life Sciences Limited on June 20, 2025 through an on-market transaction. Before the sale, TPG held 5,15,48,272 shares (24.73%); after the sale, its holding has come down to 3,07,06,833 shares (14.73%). TPG is not part of the promoter or promoter group. The disclosure is filed under Regulation 29(2) of the SEBI SAST Regulations, 2011, and no persons acting in concert have been identified. This is a significant PE exit of around 2.08 crore shares worth substantial value.
This is a meaningful PE sell-down that could weigh on the stock in the short term due to increased float and potential supply-side pressure. However, TPG still retains a 14.73% stake, suggesting it is a partial exit rather than a complete withdrawal. Retail investors should monitor price action and volume closely around any further TPG disclosures.